Mycosis Fungoides (MF) - Market Insights, Epidemiology and Market Forecast-2028
This report can be delivered to the clients within 24 Hours
DelveInsight’s ‘Mycosis Fungoides (MF) - Market Insights, Epidemiology and Market Forecast-2028’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Mycosis Fungoides (MF) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Mycosis Fungoides (MF) from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Geography Covered
Mycosis Fungoides (MF) - Disease Understanding and Treatment Algorithm
According to the WHO-EORTC classification for cutaneous lymphomas, Mycosis fungoides (MF) is a commonly epidermotropic CTCL characterized by a proliferation of small-to medium-sized T lymphocytes with cerebriform nuclei. As per the guidelines the term MF should be used only for the classical “Alibert-Bazin” type characterized by the evolution of patches, plaques, and tumors, or for variants showing a similar clinical course. MF is the most common type of CTCL and accounts for almost 50% of all primary cutaneous lymphomas.
MF generally shows a male predominance (male: female ratio 2:1) and primarily develops after the fourth decade in life. It was first described by Alibert in 1806 as the infiltration of skin by lymphocytes and named so due to its mushroom-like appearance. Initial lesions are nonspecific eczematous patches followed by the more specific plaque and tumor stage, except for 10% of patients that directly manifest with tumor. A papillary dermal infiltrate with small-to medium-sized lymphocytes with hyperchromatic and hyperconvoluted nuclei is the characteristic histological feature. Epidermotropism seen in the plaque stage is usually lost in the tumor stage.
The DelveInsight Mycosis Fungoides (MF) market report gives a thorough understanding of the Mycosis Fungoides (MF) by including details such as disease definition, types, staging, causes, clinical features, pathogenesis, symptoms and diagnostic trends. It also provides treatment algorithms and treatment guidelines for Mycosis Fungoides (MF) in the US and Europe.
Mycosis Fungoides (MF) Epidemiology
The Mycosis Fungoides (MF) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report is segmented by incident population, sub type specific incident population, stage-specific incidenct population, gender-specific incident population and diagnosed cases of Mycosis Fungoides (MF).
The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
According to DelveInsight, the incident population of Mycosis Fungoides (MF) was estimated to be 5,078 [7MM] in 2018. United States accounts for the highest Mycosis Fungoides (MF) cases, followed by EU5 (Germany, France, Italy, Spain & UK) and Japan. Among the EU5 countries UK had the highest incident patient population of Mycosis Fungoides (MF), followed by Germany.
Mycosis Fungoides (MF) Drug Chapters
This segment of the Mycosis Fungoides (MF) report encloses the detailed analysis of marketed drugs and late stage (Phase-III) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
There are currently eight approved therapies including Adcetris, Zolinza and Targretin, which are being used for the treatment of Mycosis Fungoides (MF). However these drugs have shown to be effective in managing the Mycosis Fungoides (MF) patches, plaques, and tumors, or for variants showing a similar clinical course. Also these drugs are associated with certain toxicity and subsequently virus are developing resistance against the existing batch of antivirals highlighting the need of innovative drugs. Curative drugs and vaccines remains one of the major unmet medical need in this space. Detailed chapters for all of these marketed drugs along with other promising candidates like Mechlorethamine and Uvadex have been covered in the report.
Mycosis Fungoides (MF) Market Outlook
The Mycosis Fungoides (MF) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the global market of Mycosis Fungoides (MF) was estimated to be USD 467.11 million in 2018. The United States accounts for the largest market size of Mycosis Fungoides (MF), in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain), and Japan.
The dynamics of Mycosis Fungoides (MF) market is anticipated to change in the coming years owing to the expected launch of emerging therapies during the forecasted period 2019-2028. Launch of potential therapies may increase market size in the coming years, assisted by an increase in diagnosed incident population of Mycosis Fungoides (MF). Upcoming therapies have the potential to create a significant positive shift in the Mycosis Fungoides (MF) market size. The United States accounts for the largest market size of Mycosis Fungoides (MF), in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain), and Japan.
Mycosis Fungoides (MF) Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The market size of Mycosis Fungoides (MF) includes the drug-uptake for individual therapies, which is further segmented on the basis of market size and market share by Line of therapy and Route of Administration.
To counter current unmet needs of the market and to provide better treatment options for Mycosis Fungoides (MF), several companies are working robustly on developing new therapies with novel mechanism of action.
Mycosis Fungoides (MF) Report Insights
DelveInsight’s ‘Mycosis Fungoides (MF) - Market Insights, Epidemiology and Market Forecast-2028’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Mycosis Fungoides (MF) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Mycosis Fungoides (MF) from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain and the United Kingdom)
- Japan
Mycosis Fungoides (MF) - Disease Understanding and Treatment Algorithm
According to the WHO-EORTC classification for cutaneous lymphomas, Mycosis fungoides (MF) is a commonly epidermotropic CTCL characterized by a proliferation of small-to medium-sized T lymphocytes with cerebriform nuclei. As per the guidelines the term MF should be used only for the classical “Alibert-Bazin” type characterized by the evolution of patches, plaques, and tumors, or for variants showing a similar clinical course. MF is the most common type of CTCL and accounts for almost 50% of all primary cutaneous lymphomas.
MF generally shows a male predominance (male: female ratio 2:1) and primarily develops after the fourth decade in life. It was first described by Alibert in 1806 as the infiltration of skin by lymphocytes and named so due to its mushroom-like appearance. Initial lesions are nonspecific eczematous patches followed by the more specific plaque and tumor stage, except for 10% of patients that directly manifest with tumor. A papillary dermal infiltrate with small-to medium-sized lymphocytes with hyperchromatic and hyperconvoluted nuclei is the characteristic histological feature. Epidermotropism seen in the plaque stage is usually lost in the tumor stage.
The DelveInsight Mycosis Fungoides (MF) market report gives a thorough understanding of the Mycosis Fungoides (MF) by including details such as disease definition, types, staging, causes, clinical features, pathogenesis, symptoms and diagnostic trends. It also provides treatment algorithms and treatment guidelines for Mycosis Fungoides (MF) in the US and Europe.
Mycosis Fungoides (MF) Epidemiology
The Mycosis Fungoides (MF) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report is segmented by incident population, sub type specific incident population, stage-specific incidenct population, gender-specific incident population and diagnosed cases of Mycosis Fungoides (MF).
The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
According to DelveInsight, the incident population of Mycosis Fungoides (MF) was estimated to be 5,078 [7MM] in 2018. United States accounts for the highest Mycosis Fungoides (MF) cases, followed by EU5 (Germany, France, Italy, Spain & UK) and Japan. Among the EU5 countries UK had the highest incident patient population of Mycosis Fungoides (MF), followed by Germany.
Mycosis Fungoides (MF) Drug Chapters
This segment of the Mycosis Fungoides (MF) report encloses the detailed analysis of marketed drugs and late stage (Phase-III) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
There are currently eight approved therapies including Adcetris, Zolinza and Targretin, which are being used for the treatment of Mycosis Fungoides (MF). However these drugs have shown to be effective in managing the Mycosis Fungoides (MF) patches, plaques, and tumors, or for variants showing a similar clinical course. Also these drugs are associated with certain toxicity and subsequently virus are developing resistance against the existing batch of antivirals highlighting the need of innovative drugs. Curative drugs and vaccines remains one of the major unmet medical need in this space. Detailed chapters for all of these marketed drugs along with other promising candidates like Mechlorethamine and Uvadex have been covered in the report.
Mycosis Fungoides (MF) Market Outlook
The Mycosis Fungoides (MF) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the global market of Mycosis Fungoides (MF) was estimated to be USD 467.11 million in 2018. The United States accounts for the largest market size of Mycosis Fungoides (MF), in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain), and Japan.
The dynamics of Mycosis Fungoides (MF) market is anticipated to change in the coming years owing to the expected launch of emerging therapies during the forecasted period 2019-2028. Launch of potential therapies may increase market size in the coming years, assisted by an increase in diagnosed incident population of Mycosis Fungoides (MF). Upcoming therapies have the potential to create a significant positive shift in the Mycosis Fungoides (MF) market size. The United States accounts for the largest market size of Mycosis Fungoides (MF), in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain), and Japan.
Mycosis Fungoides (MF) Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The market size of Mycosis Fungoides (MF) includes the drug-uptake for individual therapies, which is further segmented on the basis of market size and market share by Line of therapy and Route of Administration.
To counter current unmet needs of the market and to provide better treatment options for Mycosis Fungoides (MF), several companies are working robustly on developing new therapies with novel mechanism of action.
Mycosis Fungoides (MF) Report Insights
- Patient Population
- Therapeutic Approaches
- Pipeline Analysis
- Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
- 10 Year Forecast
- 7MM Coverage
- Epidemiology Segmentation
- Drugs Uptake
- Highly Analyzed Market
- Key Cross Competition
- Current Treatment Practices
- Unmet Needs
- Detailed Pipeline Product Profiles
- Market Attractiveness
- Market Drivers and Barriers
- This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Mycosis Fungoides (MF) market.
- Organize sales and marketing efforts by identifying the best opportunities for Mycosis Fungoides (MF) market.
- To understand the future market competition in the Mycosis Fungoides (MF) market.
1 KEY INSIGHTS
2 MYCOSIS FUNGOIDES (MF): MARKET OVERVIEW AT A GLANCE
2.1 TOTAL MARKET SHARE (%) DISTRIBUTION OF MYCOSIS FUNGOIDES (MF) IN 2016
2.2 TOTAL MARKET SHARE (%) DISTRIBUTION OF MYCOSIS FUNGOIDES (MF) IN 2027
3 DISEASE BACKGROUND AND OVERVIEW: MYCOSIS FUNGOIDES (MF)
3.1 INTRODUCTION
3.2 TYPES
3.2.1 Clinical variants described in the WHO-EORTC Classification for Cutaneous Lymphomas
3.2.2 Mycosis Fungoides: Clinical/Histological variants described in the Literature
3.3 STAGING
3.4 CAUSES
3.5 CLINICAL FEATURES AND PATHOGENESIS
3.5.1 Immunophenotype
3.5.2 Genetic Features
3.6 SYMPTOMS
3.7 DIAGNOSIS
4 EPIDEMIOLOGY AND PATIENT POPULATION
4.1 KEY FINDINGS
5 INCIDENT POPULATION OF MYCOSIS FUNGOIDES (MF) IN 7MM
6 COUNTRY WISE-EPIDEMIOLOGY OF MYCOSIS FUNGOIDES (MF)
6.1 UNITED STATES
6.1.1 Incident Population of MF in the United States
6.1.2 Sub Type Specific Incident Population of MF in the United States
6.1.3 Gender Specific Incidence of MF in the United States
6.1.4 Stage-Specific Incidence of MF in the United States
6.2 EU5 COUNTRIES
6.3 GERMANY
6.3.1 Incident Population of MF in Germany
6.3.2 Sub Type Specific Incident Population of MF in Germany
6.3.3 Gender Specific Incidence of MF in Germany
6.3.4 Stage-Specific Incidence of MF in Germany
6.4 FRANCE
6.4.1 Incident Population of MF in France
6.4.2 Sub Type Specific Incident Population of MF in Germany
6.4.3 Gender Specific Incidence of MF in France
6.4.4 Stage-Specific Incidence of MF in France
6.5 ITALY
6.5.1 Incident Population of MF in Italy
6.5.2 Sub Type Specific Incident Population of MF in Italy
6.5.3 Gender Specific Incidence of Mycosis fungoides (MF) in Italy
6.5.4 Stage-Specific Incidence of Mycosis fungoides (MF) in Italy
6.6 SPAIN
6.6.1 Incident Population of MF in Spain
6.6.2 Sub Type Specific Incident Population of MF in Spain
6.6.3 Gender Specific Incidence of MF in Spain
6.6.4 Stage-Specific Incidence of Mycosis fungoides (MF) in Spain
6.7 THE UNITED KINGDOM
6.7.1 Incident Population of MF in the United Kingdom
6.7.2 Sub Type Specific Incident Population of MF in the United Kingdom
6.7.3 Gender Specific Incidence of MF in the United Kingdom
6.7.4 Stage-Specific Incidence of Mycosis fungoides (MF) in UK
6.8 JAPAN
6.8.1 Incident Population of MF in Japan
6.8.2 Sub Type Specific Incident Population of MF in Japan
6.8.3 Gender Specific Incidence of MF in Japan
6.8.4 Stage-Specific Incidence of Mycosis fungoides (MF) in Japan
7 TREATMENT ALGORITHM, CURRENT TREATMENT, AND MEDICAL PRACTICES
7.1 INTERNATIONAL LYMPHOMA RADIATION ONCOLOGY GROUP GUIDELINES FOR MODERN RADIATION THERAPY FOR PRIMARY CUTANEOUS LYMPHOMAS
7.2 UNITED STATES
7.2.1 NCCN Guidelines
7.3 EUROPE
7.3.1 ESMO Guidelines
7.3.2 Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group Guidelines
7.3.3 EORTC recommendations for the treatment of mycosis fungoides/Seґzary syndrome
8 UNMET NEEDS
9 MARKETED DRUGS
9.1 ISTODAX (ROMIDEPSIN): CELGENE CORPORATION
9.1.1 Drug Description
9.1.2 Mechanism of Action:
9.1.3 Regulatory Milestones
9.1.4 Advantages and Disadvantages
9.1.5 Safety and Efficacy
9.1.6 Advantages & Disadvantages
9.1.7 Product Profile
9.2 POTELEGIO (MOGAMULIZUMAB): KYOWA HAKKO KIRIN CO, LTD.
9.2.1 Drug Description
9.2.2 Mechanism of Action
9.2.3 Regulatory Milestones
9.2.4 Advantages & Disadvantages
9.2.5 Safety and Efficacy
9.2.6 Product Profile
9.3 VALCHLOR/ LEDAGA (MECHLORETHAMINE): ACTELION
9.3.1 Drug Description
9.3.2 Mechanism of Action
9.3.3 Regulatory Milestones
9.3.4 Advantages & Disadvantages
9.3.5 Safety and Efficacy
9.3.6 Product Profile
9.4 UVADEX (METHOXSALEN): MALLINCKRODT PHARMACEUTICALS
9.4.1 Drug Description
9.4.2 Mechanism of Action
9.4.3 Regulatory Milestones
9.4.4 Advantages & Disadvantages
9.4.5 Safety and Efficacy
9.4.6 Product Profile
9.5 TARGRETIN (BEXAROTENE): EISAI CO., LTD.
9.5.1 Drug Description
9.5.2 Mechanism of Action
9.5.3 Regulatory Milestones
9.5.4 Advantages & Disadvantages
9.5.5 Safety and Efficacy of Targretin
9.5.6 Product Profile
9.6 ZOLINZA (VORINOSTAT): MERCK SHARP & DOHME CORP.
9.6.1 Drug Description
9.6.2 Mechanism of Action
9.6.3 Advantages & Disadvantages
9.6.4 Safety and Efficacy of Zolinza
9.6.5 Product Profile
9.7 ADCETRIS (BRENTUXIMAB VEDOTIN): SEATTLE GENETICS
9.7.1 Drug Description
9.7.2 Mechanism of Action
9.7.3 Regulatory Milestones
9.7.4 Advantages & Disadvantages
9.7.5 Safety and Efficacy of Adcetris
9.7.6 Product Profile
10 EMERGING THERAPIES
10.1 PHASE-III DRUGS ANALYSIS – MONOCLONAL ANTIBODIES AND PHOTODYNAMIC THERAPY
10.2 PHASE-II DRUGS ANALYSIS - HISTONE DEACETYLASE (HDAC) INHIBITORS
10.3 SGX301: SOLIGENIX
10.3.1 Product Description
10.3.2 Regulatory Milestones
10.3.3 Clinical Development
10.3.4 Product Profile
10.4 QUISINOSTAT: JANSSEN
10.4.1 Product Description
10.4.2 Regulatory Milestones
10.4.3 Clinical Development
10.4.4 Safety and Efficacy
10.4.5 Product Profile
10.5 RESMINOSTAT: 4SC AG
10.5.1 Product Description
10.5.2 Regulatory Milestones
10.5.3 Clinical Development
10.5.4 Product Profile
10.6 REMETINOSTAT: MEDIVIR AB
10.6.1 Product Description
10.6.2 Regulatory Milestones
10.6.3 Clinical Development
10.6.4 Safety and Efficacy
10.6.5 Product Profile
11 MYCOSIS FUNGOIDES (MF): 7 MAJOR MARKET ANALYSIS
11.1 KEY FINDINGS
11.2 ASSUMPTIONS AND CAVEATS
11.3 TOTAL MARKET SIZE OF MYCOSIS FUNGOIDES (MF) IN 7MM
11.3 EARLY STAGE MARKET SIZE OF MYCOSIS FUNGOIDES (MF) IN 7 MM
11.4 LATE STAGE MARKET SIZE OF MYCOSIS FUNGOIDES (MF) IN 7 MM
12 THE UNITED STATES MARKET OUTLOOK
12.1 UNITED STATES MARKET SIZE
12.1.1 Total Market size of Mycosis fungoides (MF) in US
12.1.2 Early Stage Market Size of MF by First Line of Therapies in US
12.1.3 Early Stage Market Size of MF by Second Line of Therapies in US
12.1.4 Late Stage Market Size of MF by First Line of Therapies in US
12.1.5 Late Stage Market Size of MF by Second Line of Therapies in US
13 EU-5 COUNTRIES: MARKET OUTLOOK
13.1 GERMANY
13.1.1 Total Market size of Mycosis fungoides (MF) in Germany
13.1.2 Early Stage Market Size of MF by First Line of Therapies in Germany
13.1.3 Early Stage Market Size of MF by Second Line of Therapies in Germany
13.1.4 Late Stage Market Size of MF by First Line of Therapies in Germany
13.1.5 Late Stage Market Size of MF by Second Line of Therapies in Germany
13.2 FRANCE
13.2.1 Total Market size of Mycosis fungoides (MF) in France
13.2.2 Early Stage Market Size of MF by First Line of Therapies in France
13.2.3 Early Stage Market Size of MF by Second Line of Therapies in France
13.2.4 Late Stage Market Size of MF by First Line of Therapies in France
13.2.5 Late Stage Market Size of MF by Second Line of Therapies in France
13.3 ITALY
13.3.1 Total Market size of Mycosis fungoides (MF) in Italy
13.3.2 Early Stage Market Size of MF by First Line of Therapies in Italy
13.3.3 Early Stage Market Size of MF by Second Line of Therapies in Italy
13.3.4 Late Stage Market Size of MF by First Line of Therapies in Italy
13.3.5 Late Stage Market Size of MF by Second Line of Therapies in Italy
13.4 SPAIN
13.4.1 Total Market size of Mycosis fungoides (MF) in Spain
13.4.2 Early Stage Market Size of MF by First Line of Therapies in Spain
13.4.3 Early Stage Market Size of MF by Second Line of Therapies in Spain
13.4.4 Late Stage Market Size of MF by First Line of Therapies in Spain
13.4.5 Late Stage Market Size of MF by Second Line of Therapies in Spain
13.5 UNITED KINGDOM
13.5.1 Total Market size of Mycosis fungoides (MF) in UK
13.5.2 Early Stage Market Size of MF by First Line of Therapies in UK
13.5.3 Early Stage Market Size of MF by Second Line of Therapies in UK
13.5.4 Late Stage Market Size of MF by First Line of Therapies in UK
13.5.5 Late Stage Market Size of MF by Second Line of Therapies in UK
13.6 JAPAN: MARKET OUTLOOK
13.6.1 Total Market size of Mycosis fungoides (MF) in Japan
13.6.2 Early Stage Market Size of MF by First Line of Therapies in Japan
13.6.3 Early Stage Market Size of MF by Second Line of Therapies in Japan
13.6.4 Late Stage Market Size of MF by First Line of Therapies in Japan
13.6.5 Late Stage Market Size of MF by Second Line of Therapies in Japan
14 MARKET DRIVERS
15 MARKET BARRIERS
16 APPENDIX
17 REPORT METHODOLOGY
17.1 SOURCES USED
18 DELVEINSIGHT CAPABILITIES
19 DISCLAIMER
20 ABOUT DELVEINSIGHT
2 MYCOSIS FUNGOIDES (MF): MARKET OVERVIEW AT A GLANCE
2.1 TOTAL MARKET SHARE (%) DISTRIBUTION OF MYCOSIS FUNGOIDES (MF) IN 2016
2.2 TOTAL MARKET SHARE (%) DISTRIBUTION OF MYCOSIS FUNGOIDES (MF) IN 2027
3 DISEASE BACKGROUND AND OVERVIEW: MYCOSIS FUNGOIDES (MF)
3.1 INTRODUCTION
3.2 TYPES
3.2.1 Clinical variants described in the WHO-EORTC Classification for Cutaneous Lymphomas
3.2.2 Mycosis Fungoides: Clinical/Histological variants described in the Literature
3.3 STAGING
3.4 CAUSES
3.5 CLINICAL FEATURES AND PATHOGENESIS
3.5.1 Immunophenotype
3.5.2 Genetic Features
3.6 SYMPTOMS
3.7 DIAGNOSIS
4 EPIDEMIOLOGY AND PATIENT POPULATION
4.1 KEY FINDINGS
5 INCIDENT POPULATION OF MYCOSIS FUNGOIDES (MF) IN 7MM
6 COUNTRY WISE-EPIDEMIOLOGY OF MYCOSIS FUNGOIDES (MF)
6.1 UNITED STATES
6.1.1 Incident Population of MF in the United States
6.1.2 Sub Type Specific Incident Population of MF in the United States
6.1.3 Gender Specific Incidence of MF in the United States
6.1.4 Stage-Specific Incidence of MF in the United States
6.2 EU5 COUNTRIES
6.3 GERMANY
6.3.1 Incident Population of MF in Germany
6.3.2 Sub Type Specific Incident Population of MF in Germany
6.3.3 Gender Specific Incidence of MF in Germany
6.3.4 Stage-Specific Incidence of MF in Germany
6.4 FRANCE
6.4.1 Incident Population of MF in France
6.4.2 Sub Type Specific Incident Population of MF in Germany
6.4.3 Gender Specific Incidence of MF in France
6.4.4 Stage-Specific Incidence of MF in France
6.5 ITALY
6.5.1 Incident Population of MF in Italy
6.5.2 Sub Type Specific Incident Population of MF in Italy
6.5.3 Gender Specific Incidence of Mycosis fungoides (MF) in Italy
6.5.4 Stage-Specific Incidence of Mycosis fungoides (MF) in Italy
6.6 SPAIN
6.6.1 Incident Population of MF in Spain
6.6.2 Sub Type Specific Incident Population of MF in Spain
6.6.3 Gender Specific Incidence of MF in Spain
6.6.4 Stage-Specific Incidence of Mycosis fungoides (MF) in Spain
6.7 THE UNITED KINGDOM
6.7.1 Incident Population of MF in the United Kingdom
6.7.2 Sub Type Specific Incident Population of MF in the United Kingdom
6.7.3 Gender Specific Incidence of MF in the United Kingdom
6.7.4 Stage-Specific Incidence of Mycosis fungoides (MF) in UK
6.8 JAPAN
6.8.1 Incident Population of MF in Japan
6.8.2 Sub Type Specific Incident Population of MF in Japan
6.8.3 Gender Specific Incidence of MF in Japan
6.8.4 Stage-Specific Incidence of Mycosis fungoides (MF) in Japan
7 TREATMENT ALGORITHM, CURRENT TREATMENT, AND MEDICAL PRACTICES
7.1 INTERNATIONAL LYMPHOMA RADIATION ONCOLOGY GROUP GUIDELINES FOR MODERN RADIATION THERAPY FOR PRIMARY CUTANEOUS LYMPHOMAS
7.2 UNITED STATES
7.2.1 NCCN Guidelines
7.3 EUROPE
7.3.1 ESMO Guidelines
7.3.2 Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group Guidelines
7.3.3 EORTC recommendations for the treatment of mycosis fungoides/Seґzary syndrome
8 UNMET NEEDS
9 MARKETED DRUGS
9.1 ISTODAX (ROMIDEPSIN): CELGENE CORPORATION
9.1.1 Drug Description
9.1.2 Mechanism of Action:
9.1.3 Regulatory Milestones
9.1.4 Advantages and Disadvantages
9.1.5 Safety and Efficacy
9.1.6 Advantages & Disadvantages
9.1.7 Product Profile
9.2 POTELEGIO (MOGAMULIZUMAB): KYOWA HAKKO KIRIN CO, LTD.
9.2.1 Drug Description
9.2.2 Mechanism of Action
9.2.3 Regulatory Milestones
9.2.4 Advantages & Disadvantages
9.2.5 Safety and Efficacy
9.2.6 Product Profile
9.3 VALCHLOR/ LEDAGA (MECHLORETHAMINE): ACTELION
9.3.1 Drug Description
9.3.2 Mechanism of Action
9.3.3 Regulatory Milestones
9.3.4 Advantages & Disadvantages
9.3.5 Safety and Efficacy
9.3.6 Product Profile
9.4 UVADEX (METHOXSALEN): MALLINCKRODT PHARMACEUTICALS
9.4.1 Drug Description
9.4.2 Mechanism of Action
9.4.3 Regulatory Milestones
9.4.4 Advantages & Disadvantages
9.4.5 Safety and Efficacy
9.4.6 Product Profile
9.5 TARGRETIN (BEXAROTENE): EISAI CO., LTD.
9.5.1 Drug Description
9.5.2 Mechanism of Action
9.5.3 Regulatory Milestones
9.5.4 Advantages & Disadvantages
9.5.5 Safety and Efficacy of Targretin
9.5.6 Product Profile
9.6 ZOLINZA (VORINOSTAT): MERCK SHARP & DOHME CORP.
9.6.1 Drug Description
9.6.2 Mechanism of Action
9.6.3 Advantages & Disadvantages
9.6.4 Safety and Efficacy of Zolinza
9.6.5 Product Profile
9.7 ADCETRIS (BRENTUXIMAB VEDOTIN): SEATTLE GENETICS
9.7.1 Drug Description
9.7.2 Mechanism of Action
9.7.3 Regulatory Milestones
9.7.4 Advantages & Disadvantages
9.7.5 Safety and Efficacy of Adcetris
9.7.6 Product Profile
10 EMERGING THERAPIES
10.1 PHASE-III DRUGS ANALYSIS – MONOCLONAL ANTIBODIES AND PHOTODYNAMIC THERAPY
10.2 PHASE-II DRUGS ANALYSIS - HISTONE DEACETYLASE (HDAC) INHIBITORS
10.3 SGX301: SOLIGENIX
10.3.1 Product Description
10.3.2 Regulatory Milestones
10.3.3 Clinical Development
10.3.4 Product Profile
10.4 QUISINOSTAT: JANSSEN
10.4.1 Product Description
10.4.2 Regulatory Milestones
10.4.3 Clinical Development
10.4.4 Safety and Efficacy
10.4.5 Product Profile
10.5 RESMINOSTAT: 4SC AG
10.5.1 Product Description
10.5.2 Regulatory Milestones
10.5.3 Clinical Development
10.5.4 Product Profile
10.6 REMETINOSTAT: MEDIVIR AB
10.6.1 Product Description
10.6.2 Regulatory Milestones
10.6.3 Clinical Development
10.6.4 Safety and Efficacy
10.6.5 Product Profile
11 MYCOSIS FUNGOIDES (MF): 7 MAJOR MARKET ANALYSIS
11.1 KEY FINDINGS
11.2 ASSUMPTIONS AND CAVEATS
11.3 TOTAL MARKET SIZE OF MYCOSIS FUNGOIDES (MF) IN 7MM
11.3 EARLY STAGE MARKET SIZE OF MYCOSIS FUNGOIDES (MF) IN 7 MM
11.4 LATE STAGE MARKET SIZE OF MYCOSIS FUNGOIDES (MF) IN 7 MM
12 THE UNITED STATES MARKET OUTLOOK
12.1 UNITED STATES MARKET SIZE
12.1.1 Total Market size of Mycosis fungoides (MF) in US
12.1.2 Early Stage Market Size of MF by First Line of Therapies in US
12.1.3 Early Stage Market Size of MF by Second Line of Therapies in US
12.1.4 Late Stage Market Size of MF by First Line of Therapies in US
12.1.5 Late Stage Market Size of MF by Second Line of Therapies in US
13 EU-5 COUNTRIES: MARKET OUTLOOK
13.1 GERMANY
13.1.1 Total Market size of Mycosis fungoides (MF) in Germany
13.1.2 Early Stage Market Size of MF by First Line of Therapies in Germany
13.1.3 Early Stage Market Size of MF by Second Line of Therapies in Germany
13.1.4 Late Stage Market Size of MF by First Line of Therapies in Germany
13.1.5 Late Stage Market Size of MF by Second Line of Therapies in Germany
13.2 FRANCE
13.2.1 Total Market size of Mycosis fungoides (MF) in France
13.2.2 Early Stage Market Size of MF by First Line of Therapies in France
13.2.3 Early Stage Market Size of MF by Second Line of Therapies in France
13.2.4 Late Stage Market Size of MF by First Line of Therapies in France
13.2.5 Late Stage Market Size of MF by Second Line of Therapies in France
13.3 ITALY
13.3.1 Total Market size of Mycosis fungoides (MF) in Italy
13.3.2 Early Stage Market Size of MF by First Line of Therapies in Italy
13.3.3 Early Stage Market Size of MF by Second Line of Therapies in Italy
13.3.4 Late Stage Market Size of MF by First Line of Therapies in Italy
13.3.5 Late Stage Market Size of MF by Second Line of Therapies in Italy
13.4 SPAIN
13.4.1 Total Market size of Mycosis fungoides (MF) in Spain
13.4.2 Early Stage Market Size of MF by First Line of Therapies in Spain
13.4.3 Early Stage Market Size of MF by Second Line of Therapies in Spain
13.4.4 Late Stage Market Size of MF by First Line of Therapies in Spain
13.4.5 Late Stage Market Size of MF by Second Line of Therapies in Spain
13.5 UNITED KINGDOM
13.5.1 Total Market size of Mycosis fungoides (MF) in UK
13.5.2 Early Stage Market Size of MF by First Line of Therapies in UK
13.5.3 Early Stage Market Size of MF by Second Line of Therapies in UK
13.5.4 Late Stage Market Size of MF by First Line of Therapies in UK
13.5.5 Late Stage Market Size of MF by Second Line of Therapies in UK
13.6 JAPAN: MARKET OUTLOOK
13.6.1 Total Market size of Mycosis fungoides (MF) in Japan
13.6.2 Early Stage Market Size of MF by First Line of Therapies in Japan
13.6.3 Early Stage Market Size of MF by Second Line of Therapies in Japan
13.6.4 Late Stage Market Size of MF by First Line of Therapies in Japan
13.6.5 Late Stage Market Size of MF by Second Line of Therapies in Japan
14 MARKET DRIVERS
15 MARKET BARRIERS
16 APPENDIX
17 REPORT METHODOLOGY
17.1 SOURCES USED
18 DELVEINSIGHT CAPABILITIES
19 DISCLAIMER
20 ABOUT DELVEINSIGHT
LIST OF TABLES
Table 1: ISCL/EORTC revision to the classification of MF and SS
Table 2: Recommended evaluation/initial staging of the patient with mycosis fungoides
Table 3: Total Incident population of Mycosis fungoides (MF) in the 7MM (2016-2027)
Table 4: Incident Population of Mycosis fungoides in the US (2016-2027)
Table 5: Sub-type Specific Incidence of Mycosis fungoides in the US (2016-2027)
Table 6: Gender Specific Incidence of Mycosis fungoides (MF) in the US (2016-2027)
Table 7: Stage-Specific Incidence of Mycosis fungoides in the US (2016-2027)
Table 8: Late Stage-Specific Incidence of Mycosis fungoides in the US (2016-2027)
Table 9: Incident Population of Mycosis fungoides in the US (2016-2027)
Table 10: Sub-type Specific Incidence of Mycosis fungoides in Germany (2016-2027)
Table 11: Gender Specific Incidence of Mycosis fungoides (MF) in the US (2016-2027)
Table 12: Stage-Specific Incidence of Mycosis fungoides in Germany (2016-2027)
Table 13: Late Stage-Specific Incidence of Mycosis fungoides in the US (2016-2027)
Table 14: Incident Population of Mycosis fungoides in France (2016-2027)
Table 15: Sub-type Specific Incidence of Mycosis fungoides in France (2016-2027)
Table 16: Gender Specific Incidence of Mycosis fungoides (MF) in the US (2016-2027)
Table 17: Stage-Specific Incidence of Mycosis fungoides in France (2016-2027)
Table 18: Late Stage-Specific Incidence of Mycosis fungoides in France (2016-2027)
Table 19: Incident Population of Mycosis fungoides in Italy (2016-2027)
Table 20: Sub-type Specific Incidence of Mycosis fungoides in Italy (2016-2027)
Table 21: Gender Specific Incidence of Mycosis fungoides in Italy (2016-2027)
Table 22: Stage-Specific Incidence of Mycosis fungoides in Italy (2016-2027)
Table 23: Incident Population of Mycosis fungoides in Spain (2016-2027)
Table 24: Sub-type Specific Incidence of Mycosis fungoides in Spain (2016-2027)
Table 25: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2016-2027)
Table 26: Stage-Specific Incidence of Mycosis fungoides in Spain (2016-2027)
Table 27: Incident Population of Mycosis fungoides in UK (2016-2027)
Table 28: Sub-type Specific Incidence of Mycosis fungoides in UK (2016-2027)
Table 29: Gender Specific Incidence of Mycosis fungoides in UK (2016-2027)
Table 30: Stage-Specific Incidence of Mycosis fungoides in UK (2016-2027)
Table 31: Incident Population of Mycosis fungoides in Japan (2016-2027)
Table 32: Sub-type Specific Incidence of Mycosis fungoides in Japan (2016-2027)
Table 33: Gender Specific Incidence of Mycosis fungoides in Japan (2016-2027)
Table 34: Stage-Specific Incidence of Mycosis fungoides in Japan (2016-2027)
Table 35 : Recommendations for treatment of CTCL by Radiation Therapy
Table 36: BAD Guidelines for Mycosis Fungoides and Sezary Syndrome
Table 37 : Recommendations for treatment of MF stages IA, IB, and IIA
Table 38: Market Size- Forecast Parameters and Assumptions
Table 39: 7 Major Market Size of Mycosis fungoides (MF) in USD Million (2016-2027)
Table 40: 7 Major Market Size of Early Stage Mycosis fungoides (MF) in USD Million (2016-2027)
Table 41: 7 Major Market Size of Late Stage Mycosis fungoides (MF) in USD Million (2016-2027)
Table 42: United States Market Size of Mycosis fungoides (MF) in USD Million (2016-2027)
Table 43: Early Stage Market size of MF by First line of therapies in the US, in USD Million (2016-2027)
Table 44: Early Stage Market size of MF by Second line of therapies in the US, in USD Million (2016-2027)
Table 45: Late Stage Market size of MF by First line of therapies in the US, in USD Million (2016-2027)
Table 46: Late Stage Market size of MF by Second line of therapies in the US, in USD Million (2016-2027)
Table 47: Germany Market Size of Mycosis fungoides (MF) in USD Million (2016-2027)
Table 48: Early Stage Market size of MF by First line of therapies in Germany, in USD Million (2016-2027)
Table 49: Early Stage Market size of MF by Second line of therapies in Germany, in USD Million (2016-2027)
Table 50: Late Stage Market size of MF by First line of therapies in Germany, in USD Million (2016-2027)
Table 51: Late Stage Market size of MF by Second line of therapies in Germany, in USD Million (2016-2027)
Table 52: French Market Size of Mycosis fungoides (MF) in USD Million (2016-2027)
Table 53: Early Stage Market size of MF by First line of therapies in France, in USD Million (2016-2027)
Table 54: Early Stage Market size of MF by Second line of therapies in France, in USD Million (2016-2027)
Table 55: Late Stage Market size of MF by First line of therapies in France, in USD Million (2016-2027)
Table 56: Late Stage Market size of MF by Second line of therapies in France, in USD Million (2016-2027)
Table 57: Italian Market Size of Mycosis fungoides (MF) in USD Million (2016-2027)
Table 58: Early Stage Market size of MF by First line of therapies in Italy, in USD Million (2016-2027)
Table 59: Early Stage Market size of MF by Second line of therapies in Italy, in USD Million (2016-2027)
Table 60: Late Stage Market size of MF by First line of therapies in Italy, in USD Million (2016-2027)
Table 61: Late Stage Market size of MF by Second line of therapies in Italy, in USD Million (2016-2027)
Table 62: Spanish Market Size of Mycosis fungoides (MF) in USD Million (2016-2027)
Table 63: Early Stage Market size of MF by First line of therapies in Spain, in USD Million (2016-2027)
Table 64: Early Stage Market size of MF by Second line of therapies in Spain, in USD Million (2016-2027)
Table 65: Late Stage Market size of MF by First line of therapies in Spain, in USD Million (2016-2027)
Table 66: Late Stage Market size of MF by Second line of therapies in Spain, in USD Million (2016-2027)
Table 67: UK Market Size of Mycosis fungoides (MF) in USD Million (2016-2027)
Table 68: Early Stage Market size of MF by First line of therapies in UK, in USD Million (2016-2027)
Table 69: Early Stage Market size of MF by Second line of therapies in UK, in USD Million (2016-2027)
Table 70: Late Stage Market size of MF by First line of therapies in UK, in USD Million (2016-2027)
Table 71: Late Stage Market size of MF by Second line of therapies in UK, in USD Million (2016-2027)
Table 72: Japanese Market Size of Mycosis fungoides (MF) in USD Million (2016-2027)
Table 73: Early Stage Market size of MF by First line of therapies in Japan, in USD Million (2016-2027)
Table 74: Early Stage Market size of MF by Second line of therapies in Japan, in USD Million (2016-2027)
Table 75: Late Stage Market size of MF by First line of therapies in Japan, in USD Million (2016-2027)
Table 76: Late Stage Market size of MF by Second line of therapies in Japan, in USD Million (2016-2027)
Table 1: ISCL/EORTC revision to the classification of MF and SS
Table 2: Recommended evaluation/initial staging of the patient with mycosis fungoides
Table 3: Total Incident population of Mycosis fungoides (MF) in the 7MM (2016-2027)
Table 4: Incident Population of Mycosis fungoides in the US (2016-2027)
Table 5: Sub-type Specific Incidence of Mycosis fungoides in the US (2016-2027)
Table 6: Gender Specific Incidence of Mycosis fungoides (MF) in the US (2016-2027)
Table 7: Stage-Specific Incidence of Mycosis fungoides in the US (2016-2027)
Table 8: Late Stage-Specific Incidence of Mycosis fungoides in the US (2016-2027)
Table 9: Incident Population of Mycosis fungoides in the US (2016-2027)
Table 10: Sub-type Specific Incidence of Mycosis fungoides in Germany (2016-2027)
Table 11: Gender Specific Incidence of Mycosis fungoides (MF) in the US (2016-2027)
Table 12: Stage-Specific Incidence of Mycosis fungoides in Germany (2016-2027)
Table 13: Late Stage-Specific Incidence of Mycosis fungoides in the US (2016-2027)
Table 14: Incident Population of Mycosis fungoides in France (2016-2027)
Table 15: Sub-type Specific Incidence of Mycosis fungoides in France (2016-2027)
Table 16: Gender Specific Incidence of Mycosis fungoides (MF) in the US (2016-2027)
Table 17: Stage-Specific Incidence of Mycosis fungoides in France (2016-2027)
Table 18: Late Stage-Specific Incidence of Mycosis fungoides in France (2016-2027)
Table 19: Incident Population of Mycosis fungoides in Italy (2016-2027)
Table 20: Sub-type Specific Incidence of Mycosis fungoides in Italy (2016-2027)
Table 21: Gender Specific Incidence of Mycosis fungoides in Italy (2016-2027)
Table 22: Stage-Specific Incidence of Mycosis fungoides in Italy (2016-2027)
Table 23: Incident Population of Mycosis fungoides in Spain (2016-2027)
Table 24: Sub-type Specific Incidence of Mycosis fungoides in Spain (2016-2027)
Table 25: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2016-2027)
Table 26: Stage-Specific Incidence of Mycosis fungoides in Spain (2016-2027)
Table 27: Incident Population of Mycosis fungoides in UK (2016-2027)
Table 28: Sub-type Specific Incidence of Mycosis fungoides in UK (2016-2027)
Table 29: Gender Specific Incidence of Mycosis fungoides in UK (2016-2027)
Table 30: Stage-Specific Incidence of Mycosis fungoides in UK (2016-2027)
Table 31: Incident Population of Mycosis fungoides in Japan (2016-2027)
Table 32: Sub-type Specific Incidence of Mycosis fungoides in Japan (2016-2027)
Table 33: Gender Specific Incidence of Mycosis fungoides in Japan (2016-2027)
Table 34: Stage-Specific Incidence of Mycosis fungoides in Japan (2016-2027)
Table 35 : Recommendations for treatment of CTCL by Radiation Therapy
Table 36: BAD Guidelines for Mycosis Fungoides and Sezary Syndrome
Table 37 : Recommendations for treatment of MF stages IA, IB, and IIA
Table 38: Market Size- Forecast Parameters and Assumptions
Table 39: 7 Major Market Size of Mycosis fungoides (MF) in USD Million (2016-2027)
Table 40: 7 Major Market Size of Early Stage Mycosis fungoides (MF) in USD Million (2016-2027)
Table 41: 7 Major Market Size of Late Stage Mycosis fungoides (MF) in USD Million (2016-2027)
Table 42: United States Market Size of Mycosis fungoides (MF) in USD Million (2016-2027)
Table 43: Early Stage Market size of MF by First line of therapies in the US, in USD Million (2016-2027)
Table 44: Early Stage Market size of MF by Second line of therapies in the US, in USD Million (2016-2027)
Table 45: Late Stage Market size of MF by First line of therapies in the US, in USD Million (2016-2027)
Table 46: Late Stage Market size of MF by Second line of therapies in the US, in USD Million (2016-2027)
Table 47: Germany Market Size of Mycosis fungoides (MF) in USD Million (2016-2027)
Table 48: Early Stage Market size of MF by First line of therapies in Germany, in USD Million (2016-2027)
Table 49: Early Stage Market size of MF by Second line of therapies in Germany, in USD Million (2016-2027)
Table 50: Late Stage Market size of MF by First line of therapies in Germany, in USD Million (2016-2027)
Table 51: Late Stage Market size of MF by Second line of therapies in Germany, in USD Million (2016-2027)
Table 52: French Market Size of Mycosis fungoides (MF) in USD Million (2016-2027)
Table 53: Early Stage Market size of MF by First line of therapies in France, in USD Million (2016-2027)
Table 54: Early Stage Market size of MF by Second line of therapies in France, in USD Million (2016-2027)
Table 55: Late Stage Market size of MF by First line of therapies in France, in USD Million (2016-2027)
Table 56: Late Stage Market size of MF by Second line of therapies in France, in USD Million (2016-2027)
Table 57: Italian Market Size of Mycosis fungoides (MF) in USD Million (2016-2027)
Table 58: Early Stage Market size of MF by First line of therapies in Italy, in USD Million (2016-2027)
Table 59: Early Stage Market size of MF by Second line of therapies in Italy, in USD Million (2016-2027)
Table 60: Late Stage Market size of MF by First line of therapies in Italy, in USD Million (2016-2027)
Table 61: Late Stage Market size of MF by Second line of therapies in Italy, in USD Million (2016-2027)
Table 62: Spanish Market Size of Mycosis fungoides (MF) in USD Million (2016-2027)
Table 63: Early Stage Market size of MF by First line of therapies in Spain, in USD Million (2016-2027)
Table 64: Early Stage Market size of MF by Second line of therapies in Spain, in USD Million (2016-2027)
Table 65: Late Stage Market size of MF by First line of therapies in Spain, in USD Million (2016-2027)
Table 66: Late Stage Market size of MF by Second line of therapies in Spain, in USD Million (2016-2027)
Table 67: UK Market Size of Mycosis fungoides (MF) in USD Million (2016-2027)
Table 68: Early Stage Market size of MF by First line of therapies in UK, in USD Million (2016-2027)
Table 69: Early Stage Market size of MF by Second line of therapies in UK, in USD Million (2016-2027)
Table 70: Late Stage Market size of MF by First line of therapies in UK, in USD Million (2016-2027)
Table 71: Late Stage Market size of MF by Second line of therapies in UK, in USD Million (2016-2027)
Table 72: Japanese Market Size of Mycosis fungoides (MF) in USD Million (2016-2027)
Table 73: Early Stage Market size of MF by First line of therapies in Japan, in USD Million (2016-2027)
Table 74: Early Stage Market size of MF by Second line of therapies in Japan, in USD Million (2016-2027)
Table 75: Late Stage Market size of MF by First line of therapies in Japan, in USD Million (2016-2027)
Table 76: Late Stage Market size of MF by Second line of therapies in Japan, in USD Million (2016-2027)
LIST OF FIGURES
Figure 1: WHO-EORTC based sub types of Mycosis fungoides (MF)
Figure 2: Staging of Cutaneous T-Cell Lymphoma: TNMB Classification
Figure 3: Pathogenesis of Mycosis fungoides
Figure 4: Total Incident Patient Population of MF in the 7MM (2016-2027)
Figure 5: Incident Population of Mycosis fungoides in the US (2016-2027)
Figure 6: Sub-type Specific Incidence of Mycosis fungoides in the US (2016-2027)
Figure 7: Gender Specific Incidence of Mycosis fungoides (MF) in the US (2016-2027)
Figure 8: Stage-Specific Incidence of MF in the US (2016-2027)
Figure 9: Late Stage-Specific Incidence of Mycosis fungoides in the US (2016-2027)
Figure 10: Incident Population of Mycosis fungoides in Germany (2016-2027)
Figure 11: Sub-type Specific Incidence of Mycosis fungoides in the US (2016-2027)
Figure 12: Gender Specific Incidence of Mycosis fungoides (MF) in the US (2016-2027)
Figure 13: Stage-Specific Incidence of MF in Germany (2016-2027)
Figure 14: Late Stage-Specific Incidence of Mycosis fungoides in the US (2016-2027)
Figure 15: Incident Population of Mycosis fungoides in France (2016-2027)
Figure 16: Sub-type Specific Incidence of Mycosis fungoides in France (2016-2027)
Figure 17: Gender Specific Incidence of Mycosis fungoides (MF) in France (2016-2027)
Figure 18: Stage-Specific Incidence of MF in France (2016-2027)
Figure 19: Late Stage-Specific Incidence of Mycosis fungoides in France (2016-2027)
Figure 20: Incident Population of Mycosis fungoides in Italy (2016-2027)
Figure 21: Sub-type Specific Incidence of Mycosis fungoides in Italy (2016-2027)
Figure 22: Gender Specific Incidence of Mycosis fungoides in Italy (2016-2027)
Figure 23: Stage-Specific Incidence of MF in Italy (2016-2027)
Figure 24: Incident Population of Mycosis fungoides in Spain (2016-2027)
Figure 25: Sub-type Specific Incidence of Mycosis fungoides in Spain (2016-2027)
Figure 26: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2016-2027)
Figure 27: Stage-Specific Incidence of MF in Spain (2016-2027)
Figure 28: Incident Population of Mycosis fungoides in UK (2016-2027)
Figure 29: Sub-type Specific Incidence of Mycosis fungoides in UK (2016-2027)
Figure 30: Gender Specific Incidence of Mycosis fungoides in UK (2016-2027)
Figure 31: Stage-Specific Incidence of MF in UK (2016-2027)
Figure 32: Incident Population of Mycosis fungoides in Japan (2016-2027)
Figure 33: Sub-type Specific Incidence of Mycosis fungoides in Japan (2016-2027)
Figure 34: Gender Specific Incidence of Mycosis fungoides in Japan (2016-2027)
Figure 35: Stage-Specific Incidence of MF in Japan (2016-2027)
Figure 36: Treatment Algorithm of Mycosis Fungoides
Figure 37: Treatment Algorithm of Cutaneous T- Cell Lymphoma
Figure 38:Treatment for Stage IA of Cutaneous T- Cell Lymphoma
Figure 39:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma
Figure 40:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma
Figure 41:Treatment for Stage III of Cutaneous T- Cell Lymphoma
Figure 42:Treatment for Stage IV of Cutaneous T- Cell Lymphoma
Figure 43:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders
Figure 44:Treatment for Lymphomatoid papulosis
Figure 45: Unmet Needs of Cutaneous T- Cell Lymphoma (CTCL)
Figure 46: 7 Major Market Size of Mycosis fungoides (MF) in USD Million (2016-2027)
Figure 47: 7MM Size of Early Stage Mycosis fungoides (MF) in USD Million (2016-2027)
Figure 48: 7MM Size of Late Stage MF in USD Million (2016-2027)
Figure 49: Market Size of Mycosis fungoides (MF) in the United States, USD Millions (2016-2027)
Figure 50: Early Stage Market size of MF by First line of therapies in the US, in USD Million (2016-2027)
Figure 51: Early Stage Market size of MF by Second line of therapies in the US, in USD Million (2016-2027)
Figure 52: Late Stage Market size of MF by First line of therapies in the US, in USD Million (2016-2027)
Figure 53: Late Stage Market size of MF by Second line of therapies in the US, in USD Million (2016-2027)
Figure 54: Market Size of Mycosis fungoides (MF) in Germany, USD Millions (2016-2027)
Figure 55: Early Stage Market size of MF by First line of therapies in Germany, in USD Million (2016-2027)
Figure 56: Early Stage Market size of MF by Second line of therapies in Germany, in USD Million (2016-2027)
Figure 57: Late Stage Market size of MF by First line of therapies in Germany, in USD Million (2016-2027)
Figure 58: Late Stage Market size of MF by Second line of therapies in Germany, in USD Million (2016-2027)
Figure 59: Market Size of Mycosis fungoides (MF) in France, USD Millions (2016-2027)
Figure 60: Early Stage Market size of MF by First line of therapies in France, in USD Million (2016-2027)
Figure 61: Early Stage Market size of MF by Second line of therapies in France, in USD Million (2016-2027)
Figure 62: Late Stage Market size of MF by First line of therapies in France, in USD Million (2016-2027)
Figure 63: Late Stage Market size of MF by Second line of therapies in France, in USD Million (2016-2027)
Figure 64: Market Size of Mycosis fungoides (MF) in Italy, USD Millions (2016-2027)
Figure 65: Early Stage Market size of MF by First line of therapies in Italy, in USD Million (2016-2027)
Figure 66: Early Stage Market size of MF by Second line of therapies in Italy, in USD Million (2016-2027)
Figure 67: Late Stage Market size of MF by First line of therapies in Italy, in USD Million (2016-2027)
Figure 68: Late Stage Market size of MF by Second line of therapies in Italy, in USD Million (2016-2027)
Figure 69: Market Size of Mycosis fungoides (MF) in Spain, USD Millions (2016-2027)
Figure 70: Early Stage Market size of MF by First line of therapies in Spain, in USD Million (2016-2027)
Figure 71: Early Stage Market size of MF by Second line of therapies in Spain, in USD Million (2016-2027)
Figure 72: Late Stage Market size of MF by First line of therapies in Spain, in USD Million (2016-2027)
Figure 73: Late Stage Market size of MF by Second line of therapies in Spain, in USD Million (2016-2027)
Figure 74: Market Size of Mycosis fungoides (MF) in UK, USD Millions (2016-2027)
Figure 75: Early Stage Market size of MF by First line of therapies in UK, in USD Million (2016-2027)
Figure 76: Early Stage Market size of MF by Second line of therapies in UK, in USD Million (2016-2027)
Figure 77: Late Stage Market size of MF by First line of therapies in UK, in USD Million (2016-2027)
Figure 78: Late Stage Market size of MF by Second line of therapies in UK, in USD Million (2016-2027)
Figure 79: Market Size of Mycosis fungoides (MF) in Japan, USD Millions (2016-2027)
Figure 80: Early Stage Market size of MF by First line of therapies in Japan, in USD Million (2016-2027)
Figure 81: Early Stage Market size of MF by Second line of therapies in Japan, in USD Million (2016-2027)
Figure 82: Late Stage Market size of MF by First line of therapies in Japan, in USD Million (2016-2027)
Figure 83: Late Stage Market size of MF by Second line of therapies in Japan, in USD Million (2016-2027)
Figure 84: Market Drivers
Figure 85:Market Barriers
Figure 1: WHO-EORTC based sub types of Mycosis fungoides (MF)
Figure 2: Staging of Cutaneous T-Cell Lymphoma: TNMB Classification
Figure 3: Pathogenesis of Mycosis fungoides
Figure 4: Total Incident Patient Population of MF in the 7MM (2016-2027)
Figure 5: Incident Population of Mycosis fungoides in the US (2016-2027)
Figure 6: Sub-type Specific Incidence of Mycosis fungoides in the US (2016-2027)
Figure 7: Gender Specific Incidence of Mycosis fungoides (MF) in the US (2016-2027)
Figure 8: Stage-Specific Incidence of MF in the US (2016-2027)
Figure 9: Late Stage-Specific Incidence of Mycosis fungoides in the US (2016-2027)
Figure 10: Incident Population of Mycosis fungoides in Germany (2016-2027)
Figure 11: Sub-type Specific Incidence of Mycosis fungoides in the US (2016-2027)
Figure 12: Gender Specific Incidence of Mycosis fungoides (MF) in the US (2016-2027)
Figure 13: Stage-Specific Incidence of MF in Germany (2016-2027)
Figure 14: Late Stage-Specific Incidence of Mycosis fungoides in the US (2016-2027)
Figure 15: Incident Population of Mycosis fungoides in France (2016-2027)
Figure 16: Sub-type Specific Incidence of Mycosis fungoides in France (2016-2027)
Figure 17: Gender Specific Incidence of Mycosis fungoides (MF) in France (2016-2027)
Figure 18: Stage-Specific Incidence of MF in France (2016-2027)
Figure 19: Late Stage-Specific Incidence of Mycosis fungoides in France (2016-2027)
Figure 20: Incident Population of Mycosis fungoides in Italy (2016-2027)
Figure 21: Sub-type Specific Incidence of Mycosis fungoides in Italy (2016-2027)
Figure 22: Gender Specific Incidence of Mycosis fungoides in Italy (2016-2027)
Figure 23: Stage-Specific Incidence of MF in Italy (2016-2027)
Figure 24: Incident Population of Mycosis fungoides in Spain (2016-2027)
Figure 25: Sub-type Specific Incidence of Mycosis fungoides in Spain (2016-2027)
Figure 26: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2016-2027)
Figure 27: Stage-Specific Incidence of MF in Spain (2016-2027)
Figure 28: Incident Population of Mycosis fungoides in UK (2016-2027)
Figure 29: Sub-type Specific Incidence of Mycosis fungoides in UK (2016-2027)
Figure 30: Gender Specific Incidence of Mycosis fungoides in UK (2016-2027)
Figure 31: Stage-Specific Incidence of MF in UK (2016-2027)
Figure 32: Incident Population of Mycosis fungoides in Japan (2016-2027)
Figure 33: Sub-type Specific Incidence of Mycosis fungoides in Japan (2016-2027)
Figure 34: Gender Specific Incidence of Mycosis fungoides in Japan (2016-2027)
Figure 35: Stage-Specific Incidence of MF in Japan (2016-2027)
Figure 36: Treatment Algorithm of Mycosis Fungoides
Figure 37: Treatment Algorithm of Cutaneous T- Cell Lymphoma
Figure 38:Treatment for Stage IA of Cutaneous T- Cell Lymphoma
Figure 39:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma
Figure 40:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma
Figure 41:Treatment for Stage III of Cutaneous T- Cell Lymphoma
Figure 42:Treatment for Stage IV of Cutaneous T- Cell Lymphoma
Figure 43:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders
Figure 44:Treatment for Lymphomatoid papulosis
Figure 45: Unmet Needs of Cutaneous T- Cell Lymphoma (CTCL)
Figure 46: 7 Major Market Size of Mycosis fungoides (MF) in USD Million (2016-2027)
Figure 47: 7MM Size of Early Stage Mycosis fungoides (MF) in USD Million (2016-2027)
Figure 48: 7MM Size of Late Stage MF in USD Million (2016-2027)
Figure 49: Market Size of Mycosis fungoides (MF) in the United States, USD Millions (2016-2027)
Figure 50: Early Stage Market size of MF by First line of therapies in the US, in USD Million (2016-2027)
Figure 51: Early Stage Market size of MF by Second line of therapies in the US, in USD Million (2016-2027)
Figure 52: Late Stage Market size of MF by First line of therapies in the US, in USD Million (2016-2027)
Figure 53: Late Stage Market size of MF by Second line of therapies in the US, in USD Million (2016-2027)
Figure 54: Market Size of Mycosis fungoides (MF) in Germany, USD Millions (2016-2027)
Figure 55: Early Stage Market size of MF by First line of therapies in Germany, in USD Million (2016-2027)
Figure 56: Early Stage Market size of MF by Second line of therapies in Germany, in USD Million (2016-2027)
Figure 57: Late Stage Market size of MF by First line of therapies in Germany, in USD Million (2016-2027)
Figure 58: Late Stage Market size of MF by Second line of therapies in Germany, in USD Million (2016-2027)
Figure 59: Market Size of Mycosis fungoides (MF) in France, USD Millions (2016-2027)
Figure 60: Early Stage Market size of MF by First line of therapies in France, in USD Million (2016-2027)
Figure 61: Early Stage Market size of MF by Second line of therapies in France, in USD Million (2016-2027)
Figure 62: Late Stage Market size of MF by First line of therapies in France, in USD Million (2016-2027)
Figure 63: Late Stage Market size of MF by Second line of therapies in France, in USD Million (2016-2027)
Figure 64: Market Size of Mycosis fungoides (MF) in Italy, USD Millions (2016-2027)
Figure 65: Early Stage Market size of MF by First line of therapies in Italy, in USD Million (2016-2027)
Figure 66: Early Stage Market size of MF by Second line of therapies in Italy, in USD Million (2016-2027)
Figure 67: Late Stage Market size of MF by First line of therapies in Italy, in USD Million (2016-2027)
Figure 68: Late Stage Market size of MF by Second line of therapies in Italy, in USD Million (2016-2027)
Figure 69: Market Size of Mycosis fungoides (MF) in Spain, USD Millions (2016-2027)
Figure 70: Early Stage Market size of MF by First line of therapies in Spain, in USD Million (2016-2027)
Figure 71: Early Stage Market size of MF by Second line of therapies in Spain, in USD Million (2016-2027)
Figure 72: Late Stage Market size of MF by First line of therapies in Spain, in USD Million (2016-2027)
Figure 73: Late Stage Market size of MF by Second line of therapies in Spain, in USD Million (2016-2027)
Figure 74: Market Size of Mycosis fungoides (MF) in UK, USD Millions (2016-2027)
Figure 75: Early Stage Market size of MF by First line of therapies in UK, in USD Million (2016-2027)
Figure 76: Early Stage Market size of MF by Second line of therapies in UK, in USD Million (2016-2027)
Figure 77: Late Stage Market size of MF by First line of therapies in UK, in USD Million (2016-2027)
Figure 78: Late Stage Market size of MF by Second line of therapies in UK, in USD Million (2016-2027)
Figure 79: Market Size of Mycosis fungoides (MF) in Japan, USD Millions (2016-2027)
Figure 80: Early Stage Market size of MF by First line of therapies in Japan, in USD Million (2016-2027)
Figure 81: Early Stage Market size of MF by Second line of therapies in Japan, in USD Million (2016-2027)
Figure 82: Late Stage Market size of MF by First line of therapies in Japan, in USD Million (2016-2027)
Figure 83: Late Stage Market size of MF by Second line of therapies in Japan, in USD Million (2016-2027)
Figure 84: Market Drivers
Figure 85:Market Barriers
